



GOVERNMENT OF PAKISTAN  
(CABINET DIVISION)  
INTELLECTUAL PROPERTY ORGANIZATION  
THE PATENT OFFICE  
**KARACHI**



To,

Dated: 21-05-2009

Mr. Munir Ahmed,  
Director (Admn.),  
IPO-Pakistan,  
**Islamabad.**

**Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE  
WEEKENDING 08-05-2009 TO BE PUBLISHED 22-05-2009 IN THE  
GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

**(Mrs. Yasmeen Abbasi)**  
Controller of Patents  
Ph: 9215488

**ENCL:**

## NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000

### 04-05-2009

- |          |  |  |
|----------|--|--|
| 363/2009 | SmithKline Beecham Corporation.<br>USA<br>(Priority 06-05-2008 USA)      | “Benzene sulfonamide thiazole and oxazole compounds”   |
| 364/2009 | SmithKline Beecham Corporation<br>USA.<br>(Priority 05-05-2008 USA)      | “Method of treating cancer using a cMet inhibitor and an ErbB inhibitor”                               |
| 365/2009 | Invista Technologies S.a r.l.<br>Switzerland<br>(Priority 06-05-2008 GB) | “Power recovery”   |
| 366/2009 | Alpinestars Research Srl.<br>Italy.<br>(Priority 02-05-2008 Italy)       | “Protecting device for the neck”   |
| 367/2009 | Sanofi-Aventis<br>France.<br>(Priority 05-05-2008 Europe)                | “Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals, |
| 368/2009 | Rich Products Corporation,<br>USA<br>(Priority 02-05-2008 USA)           | “Systems and methods for selecting flour”  |

### 05-05-2009

- |          |   |  |
|----------|---|--|
| 369/2009 | AstraZeneca AB<br>Sweden<br>(Priority 07-05-2008 USA)       | “Chemical compounds”                       |
| 370/2009 | Bo H Gimvang.<br>USA<br>(Priority 23-10-2008 USA)           | “Corrosion and abrasion resistant coating” |
| 371/2009 | H. Lundbeck A/S<br>Denmark<br>(Priority 07-05-2008 Denmark) | “Method for treating cognitive deficits”   |
| 372/2009 | AstraZeneca AB,<br>Sweden<br>(Priority 05-05-2008 USA)      | “Novel compounds 300”                      |

373/2009	Evonik Rohm GmbH, Germany (Priority 04-07-2008 Germany)	“Process for the preparation of free carboxylic acids”
374/2009	Evonik Rohm GmbH, Germany (Priority 27-06-2008 Germany)	“2-hydroxyisobutyric acid-producing recombinant cell”
375/2009	Glaxo Group Limited United Kingdom (Priority 06-05-2008 USA)	“Encapsulation of biologically active agents”
376/2009	Glaxo Group Limited United Kingdom (Priority 06-05-2008 USA)	“Encapsulation of biologically active agents”
377/2009	Glaxo Group Limited United Kingdom (Priority 06-05-2008 USA)	“Encapsulation of biologically active agents”
378/2009	Glaxo Group Limited United Kingdom (Priority 06-05-2008 USA)	“Encapsulation of biologically active agents”
379/2009	Bayer Schering Pharma Aktiengesellschaft, Germany (Priority 09-05-2008 Europe)	“Use of a virus regimen for the treatment of diseases”
380/2009	Bayer Cropscience AG, Germany (Priority 07-05-2008 Europe)	“Synergistic active compound combinations”
	<b><u>06-05-2009</u></b>	
381/2009	Actaris S.A.S., France (Priority 13-05-2008 France)	“A diaphragm gas meter with rotary distribution drive”
	<b><u>07-05-2009</u></b>	
382/2009	Boehringer Ingelheim International GmbH. Germany (Priority 25-09-2006 USA) <b>Divisional</b>	“A physiologically acceptable satl comprising substituted alkyl or cycloalkyl amides which modulate the CB2 receptor”
383/2009	Urea Casale S.A. Switzerland (Priority 14-05-2008 Europe)	“Process for producing high-quality melamine from urea”

384/2009	Syngenta Participations AG, Switzerland (Priority 12-05-2008 USA)	“Pesticidal compositions”
385/2009	Galapagos NV, Belgium (Priority 07-05-2008 USA)	“Novel compounds useful for the treatment of degenerative and inflammatory conditions”
386/2009	AiCuris GmbH & Co. KG, Germany (Priority 08-05-2008 Germany)	“Agent for the treatment and/or prophylaxis of an autoimmune disease and for the formation of regulatory T cells”
387/2009	Airlight Energy Holding SA Switzerland (Priority 07-05-2008 Switzerland)	“Trough collector for a solar power plant”
388/2009	Sanofi-Aventis France (Priority 09-05-2008 France)	“Pyrrole derivatives, their preparation and their therapeutic application”
389/2009	Sanofi-Aventis France (Priority 09-05-2008 France)	“Pyrrole derivatives, preparation thereof and therapeutic use thereof”
390/2009	Sumra Naeem. Uzma Zafar. PCSIR, Lahore, Pakistan	“A process for the preparation of aluminium diacetate monobasic”
391/2009	Dr. Shahid Mahmud. Hifza Akhtar. Dr. Muhammad Saleem. Razia Khanum. PCSIR, Lahore, Pakistan	“A process for the production of animal fat free chapstick”
392/2009	Mrs. Razia Khanum. Dr. Zahida Parveen. Dr. Shahid Mahmud. Dr. Muhammad Saleem. PCSIR, Lahore, Pakistan	“A formulation for herbal mud mask”
	<b><u>08-05-2009</u></b>	
393/2009	Abbott GmbH & Co. KG Germany Abbott Laboratories. USA (Priority 09-05-2008 USA)	“Antibodies to receptor of advanced glycation end”

394/2009	AstraZeneca AB Sweden (Priority 13-05-2008 USA)	“Novel salt 554”
395/2009	Ortloff Engineers, Ltd, USA (Priority 16-05-2008 USA)	“Liquefied natural gas and hydrocarbon gas processing “
396/2009	Plexxikon, Inc., USA (Priority 19-05-2008 USA)	“compounds and methods for kinase modulation, and indications therefore”
397/2009	Plexxikon, Inc., USA (Priority 19-05-2008 USA)	“Compounds and methods for kinase modulation, and indications therefore”
398/2009	F. L. Smidth A/S, Denmark (Priority 06-06-2008 Denmark)	“Gasification with separate calcinations”

## APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.


The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

143/2001	SmithKline Beecham p.l.c., United Kingdom	“A pyrimidinone compound” CO7D 239/56
----------	---	--

**140084**

Pyrimidone compound of formula



as inhibitor of the enzyme Lp-PLA2 and for use  
in treating atherosclerosis.


113/2002 Janssen  
Pharmaceutica N.V.,  
Belgium

“Isoxazolines compound and its use as anti-depressant”

CO7D 261/20, 241/04

**140085**

The invention concerns substituted isoxazolines compound according to Formula (I)



wherein X = CH<sub>2</sub>, N-R<sup>7</sup>, S or O, R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are certain specific substituents, Pir is an optionally substituted piperidyl or piperazyl radical and R<sup>3</sup> represents an optionally substituted aromatic homocyclic or heterocyclic ring system including a partially or completely hydrogenated hydrocarbon chain of maximum 6 atoms long with which the ring system is attached to the Pir radical and which may contain one or more heteroatoms selected from the group of O, N and S ; a process for their preparation, pharmaceutical compositions comprising them and their use as a medicine, in particular for the treatment of depression and/of anxiety and disorders of body weight. The compounds according to the invention have surprisingly been shown to have a serotonin (5-HT) reuptake inhibitor activity in combination with additional alfa2-adrenoceptor antagonist activity and show a strong anti-depressant activity without being sedative. Compound according to the invention is also suitable for treating patients with anxiety disorders and disorders of body weight. The invention also relates to novel combination of substituted isoxazolines compound having anti-depressant activity and/or anxiolytic activity and/or body weight control activity with antidepressants, anxiolytics and/or antipsychotics to improve efficacy and/or onset of action.

694/2003 Bristol-Myers Squibb Company,  
USA

“Composition and antiviral activity of substituted azaindoleoxoacetic piperazine compound”

CO7D 487/02

**140086**

This invention provides compound having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine . This compound possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

950/2007 Deere & Company,  
USA

“Drawn cotton picker”

AO1D 46/08

**140087**

One or two conventional picking units are mounted on a two-wheel, high clearance running gear or frame. A two-point hitch is coupled to the draft links of a tractor or an equal-angle hitch is coupled to the tractor drawbar. Hitch and tongue interface on the harvester facilitates sharp turn angles between the implement and the tractor through use of a pivoting member containing the driveline powering the units from the tractor. A center pivot tongue allows offset for appropriate row allgnment and provides improved maneuverability and implement steering on headlands and trun rows. A hydraulic cylinder connected to the tongue or a crossed four-bar linkage structure controls tongue angle. A basket is supported at the rear of the frame and the row units are located forwardly of the frame to provide counterbalancing forces about the wheel axis.

1093/2007 Sanofi-Aventis,  
France

“Process for preparing N-alkylnaltrexone halide compound”


CO7C 45/00

**140088**

The invention relates to a novel process for preparing N-methylnaltrexone bromide, comprising the steps consisting in:

(i) reacting N-methylnaltrexone methyl sulphate in aqueous solution with an alkaline agent chosen from the group constituted by sodium carbonate, potassium carbonate, calcium carbonate, magnesium carbonate, caesium carbonate, strontium carbonate and mixtures thereof, for a pH of the aqueous reaction medium of between 7 and 10, and then in

(ii) reacting the product obtained in (i) of the formula



with hydrobromic acid, which is added for a pH of the aqueous reaction medium of between 0.5 and 5, in order thus to obtain the N-methylnaltrexone bromide.

196/2008 Laboratorios Almirall,  
S.A.  
Spain.

“New process for preparing 3-methyl-4-phenylisoxazolo [3,4-D]pyridazin-7(6H)-one”

CO7C 213/00

**140089**

3-Methyl-4-phenylisoxazolo[3,4-d]pyridazin-7(6H)-one is prepared by reacting 1-phenylbutane-1,3-dione with ethyl 2-chloro-2-(hydroxyimino)acetate (step a) and subsequently

reacting the resulting ethyl 4-benzoyl-5-methylisoxazole-3-carboxylate with hydrazine or an hydrate thereof to yield 3-methyl-4-phenylisoxazolo[3,4-d]pyridazin-7(6H)-one (step b), which is an intermediate for producing some pyridazin-3(2H)-one compounds useful as phosphodiesterase 4 (PDE4) inhibitors. The process is characterised by using ethyl 4-benzoyl-5-methylisoxazole-3-carboxylate from (step a) without isolation in (step b).

### SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139840	F. Hoffmann-La Roche AG. Switzerland	778/1996
139841	Wyeth. USA	147/2001
139842	Syngenta Participations AG. Switzerland	131/2002
139843	Novartis AG. Switzerland	990/2002
139844	LES Laboratoires Servier. France	225/2005
139845	F. Hoffmann-LA Roche AG. Switzerland	984/2006
139846	F. Hoffmann-LA Roche AG. Switzerland	985/2006
139847	Bristol Myers Squibb Company. USA	475/2007
139848	Y.K.K. Saglik Hizmetleri Limited. Sirketi, Turkey	1040/2007

**(MRS. YASMEEN ABBASI)**  
CONTROLLER OF PATENTS  
Tel: 9215488